This video is under embargo. Please login to access this video.
Caption
Jodi Karnell, Sr. director, research, Horizon Therapeutics, discusses how HZN-7734 depletes plasmacytoid dendritic cells and demonstrates clinical benefit in cutaneous lupus. This material relates to a paper that appeared in the May 26, 2021, issue of Science Translational Medicine, published by AAAS. The paper, by J.L. Karnell at Viela Bio in Gaithersburg, MD; and colleagues was titled, "Depleting plasmacytoid dendritic cells reduces local type I interferon responses and disease activity in patients with cutaneous lupus."
Credit
Horizon Therapeutics
Usage Restrictions
Please cite the owner of the material when publishing. This material may be freely used by reporters as part of news coverage, with proper attribution. Non-reporters must contact <i>Science</i> for permission.